Quantification of liver iron with MRI: State of the art and remaining challenges

Journal of Magnetic Resonance Imaging

Volumn 40, Issue 5, 2014, Pages 1003-1021

  Hernando, Diego ^a   Levin, Yakir S ^b   Sirlin, Claude B ^b   Reeder, Scott B ^a,c,d  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d University of Wisconsin Madison   (United States)

Author keywords

Liver iron; MR relaxometry; R2; R2 ; Susceptometry

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERRITIN; IRON; TRANSFERRIN;

ARTICLE; BLOOD TRANSFUSION; CALIBRATION; CHELATION THERAPY; CHRONIC LIVER DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE MARKER; ECHOGRAPHY; FERRITIN BLOOD LEVEL; HUMAN; INTESTINE ABSORPTION; IRON BLOOD LEVEL; IRON LIVER LEVEL; IRON OVERLOAD; IRON STORAGE; LIVER BIOPSY; LIVER LEVEL; LONG TERM CARE; MAGNETISM; MATHEMATICAL PARAMETERS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOPHYSIOLOGY; RELAXATION TIME; SIGNAL NOISE RATIO; TRANSFERRIN BLOOD LEVEL; ADVERSE EFFECTS; BIOPSY; CHEMISTRY; COMPUTER ASSISTED DIAGNOSIS; HEMOCHROMATOSIS; HEMOSIDEROSIS; LIVER; PATHOLOGY; PROCEDURES; SENSITIVITY AND SPECIFICITY;

BIOPSY; BLOOD TRANSFUSION; HEMOCHROMATOSIS; HEMOSIDEROSIS; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IRON; LIVER; MAGNETIC RESONANCE IMAGING; SENSITIVITY AND SPECIFICITY;

EID: 84913607974     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.24584     Document Type: Article

References (140)

1. Andrews NC, Schmidt PJ. Iron homeostasis. Annu Rev Physiol 2007;69:69-85.
2. Alustiza JM, Castiella A, De Juan MD, Emparanza JI, Artetxe J, Uranga M. Iron overload in the liver diagnostic and quantification. Eur J Radiol 2007;61:499-506.
3. Lieu PT, Heiskala M, Peterson PA, Yang Y. The roles of iron in health and disease. Mol Aspects Med 2001;22:1-87.
4. Miret S, Simpson RJ, McKie AT. Physiology and molecular biology of dietary iron absorption. Annu Rev Nutr 2003;23:283-301.
5. Pietrangelo A. Hereditary hemochromatosis-a new look at an old disease. N Engl J Med 2004;350:2383-2397.
6. Brittenham GM, Badman DG. Noninvasive measurement of iron: report of an NIDDK workshop. Blood 2003;101:15-19.
7. Siegelman ES, Mitchell DG, Semelka RC. Abdominal iron deposition: metabolism, MR findings, and clinical importance. Radiology 1996;199:13-22.
8. Gossuin Y, Muller RN, Gillis P. Relaxation induced by ferritin: a better understanding for an improved MRI iron quantification. NMR Biomed 2004;17:427-432.
9. Sirlin CB, Reeder SB. Magnetic resonance imaging quantification of liver iron. Magn Reson Imaging Clin N Am 2010;18:359-381, ix.
10. Princiotto JV, Zapolski EJ. Difference between the two ironbinding sites of transferrin. Nature 1975;255:87-88.
11. Batts KP. Iron overload syndromes and the liver. Mod Pathol 2007;20(Suppl 1):31-39.
12. St Pierre TG, Clark PR, Chua-Anusorn W. Single spin-echo proton transverse relaxometry of iron-loaded liver. NMR Biomed 2004;17:446-458.
13. Pietrangelo A. Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. Gastroenterology 2010;139:393-408, e391-392.
14. St Pierre TG, Clark PR, Chua-anusorn W, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005;105:855-861.
15. Chu WC, Au WY, Lam WW. MRI of cardiac iron overload. J Magn Reson Imaging 2012;36:1052-1059.
16. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 2006;107:3733-3737.
17. Wood JC. Cardiac iron across different transfusion-dependent diseases. Blood Rev 2008;22(Suppl 2):14-21.
18. Adams P, Brissot P, Powell LW. EASL International Consensus Conference on Haemochromatosis. J Hepatol 2000;33:485-504.
19. Ludwig J, Hashimoto E, Porayko MK, Moyer TP, Baldus WP. Hemosiderosis in cirrhosis: a study of 447 native livers. Gastroenterology 1997;112:882-888.
20. Pirisi M, Scott CA, Avellini C, et al. Iron deposition and progression of disease in chronic hepatitis C. Role of interface hepatitis, portal inflammation, and HFE missense mutations. Am J Clin Pathol 2000;113:546-554.
21. Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011;54:328-343.
22. Bonkovsky HL, Lambrecht RW, Shan Y. Iron as a co-morbid factor in nonhemochromatotic liver disease. Alcohol 2003;30:137-144.
23. Tung BY, Emond MJ, Bronner MP, Raaka SD, Cotler SJ, Kowdley KV. Hepatitis C, iron status, and disease severity: relationship with HFE mutations. Gastroenterology 2003;124:318-326.
24. Franchini M, Targher G, Capra F, Montagnana M, Lippi G. The effect of iron depletion on chronic hepatitis C virus infection. Hepatol Int 2008;2:335-340.
25. Lambrecht RW, Sterling RK, Naishadham D, et al., Group H-CT. Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C. Gastroenterology 2011;140:1490-1500 e1493.
26. Nelson JE, Klintworth H, Kowdley KV. Iron metabolism in Nonalcoholic Fatty Liver Disease. Curr Gastroenterol Rep 2012;14:8-16.
27. Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmeyer G. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 1985;313:1256-1262.
28. Porter JB. Practical management of iron overload. Br J Haematol 2001;115:239-252.
29. Vichinsky E. Oral iron chelators and the treatment of iron overload in pediatric patients with chronic anemia. Pediatrics 2008; 121:1253-1256.
30. Kushner JP, Porter JP, Olivieri NF. Secondary iron overload. Hematol Am Soc Hematol Educ Program 2001:47-61.
31. Bassett ML, Halliday JW, Powell LW. Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis. Hepatology 1986;6:24- 29.
32. Angelucci E, Brittenham GM, McLaren CE, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 2000;343:327-331.
33. Leitch HA. Controversies surrounding iron chelation therapy for MDS. Blood Rev 2011;25:17-31.
34. Wood JC, Enriquez C, Ghugre N, et al. MRI R2 and R2∗ mapping accurately estimates hepatic iron concentration in transfusiondependent thalassemia and sickle cell disease patients. Blood 2005;106:1460-1465.
35. Rowe JW, Wands JR, Mezey E, et al. Familial hemochromatosis: characteristics of the precirrhotic stage in a large kindred. Medicine (Baltimore) 1977;56:197-211.
36. Emond MJ, Bronner MP, Carlson TH, Lin M, Labbe RF, Kowdley KV. Quantitative study of the variability of hepatic iron concentrations. Clin Chem 1999;45:340-346.
37. Kreeftenberg HG, Koopman BJ, Huizenga JR, van Vilsteren T, Wolthers BG, Gips CH. Measurement of iron in liver biopsies-a comparison of three analytical methods. Clin Chim Acta 1984; 144:255-262.
38. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001;344:495-500.
39. Copel L, Sosna J, Kruskal JB, Kane RA. Ultrasound-guided percutaneous liver biopsy: indications, risks, and technique. Surg Technol Int 2003;11:154-160.
40. Papakonstantinou O, Kostaridou S, Maris T, et al. Quantification of liver iron overload by T2 quantitative magnetic resonance imaging in thalassemia: impact of chronic hepatitis C on measurements. J Pediatr Hematol Oncol 1999;21:142-148.
41. Harmatz P, Butensky E, Quirolo K, et al. Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood 2000;96:76-79.
42. Karam LB, Disco D, Jackson SM, et al. Liver biopsy results in patients with sickle cell disease on chronic transfusions: poor correlation with ferritin levels. Pediatr Blood Cancer 2008;50: 62-65.
43. Adamkiewicz TV, Abboud MR, Paley C, et al. Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury. Blood 2009;114:4632-4638.
44. Brittenham GM, Sheth S, Allen CJ, Farrell DE. Noninvasive methods for quantitative assessment of transfusional iron overload in sickle cell disease. Semin Hematol 2001;38:37-56.
45. Schenck JF. The role of magnetic susceptibility in magnetic resonance imaging: MRI magnetic compatibility of the first and second kinds. Med Phys 1996;23:815-850.
46. Brittenham GM, Farrell DE, Harris JW, et al. Magnetic-susceptibility measurement of human iron stores. N Engl J Med 1982; 307:1671-1675.
47. Avrin WF, Kumar S. Noninvasive liver-iron measurements with a room-temperature susceptometer. Physiol Meas 2007;28:349- 361.
48. Gandon Y, Olivie D, Guyader D, et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet 2004;363:357-362.
49. Rofsky NM, Fleishaker H. CT and MRI of diffuse liver disease. Semin Ultrasound CT MR 1995;16:16-33.
50. Mortele KJ, Ros PR. Imaging of diffuse liver disease. Semin Liver Dis 2001;21:195-212.
51. Fischer MA, Reiner CS, Raptis D, et al. Quantification of liver iron content with CT-added value of dual-energy. Eur Radiol 2011;21:1727-1732.
52. Boll DT, Merkle EM. Diffuse liver disease: strategies for hepatic CT and MR imaging. Radiographics 2009;29:1591-1614.
53. Goldman IS, Winkler ML, Raper SE, et al. Increased hepatic density and phospholipidosis due to amiodarone. AJR Am J Roentgenol 1985;144:541-546.
54. De Maria M, De Simone G, Laconi A, Mercadante G, Pavone P, Rossi P. Gold storage in the liver: appearance on CT scans. Radiology 1986;159:355-356.
55. Akpinar E, Akhan O. Liver imaging findings of Wilson's disease. Eur J Radiol 2007;61:25-32.
56. Ghugre NR, Wood JC. Relaxivity-iron calibration in hepatic iron overload: probing underlying biophysical mechanisms using a Monte Carlo model. Magn Reson Med 2011;65:837-847.
57. Jensen JH, Chandra R. Theory of nonexponential NMR signal decay in liver with iron overload or superparamagnetic iron oxide particles. Magn Reson Med 2002;47:1131-1138.
58. Brooks RA, Moiny F, Gillis P. On T2-shortening by weakly magnetized particles: the chemical exchange model. Magn Reson Med 2001;45:1014-1020.
59. Gossuin Y, Roch A, Muller RN, Gillis P, Lo Bue, F. Anomalous nuclear magnetic relaxation of aqueous solutions of ferritin: an unprecedented first-order mechanism. Magn Reson Med 2002; 48:959-964.
60. Gandon Y, Guyader D, Heautot JF, et al. Hemochromatosis: diagnosis and quantification of liver iron with gradient-echo MR imaging. Radiology 1994;193:533-538.
61. Ernst O, Sergent G, Bonvarlet P, Canva-Delcambre V, Paris JC, L'Hermine C. Hepatic iron overload: diagnosis and quantification with MR imaging. AJR Am J Roentgenol 1997;168:1205-1208.
62. Bonkovsky HL, Rubin RB, Cable EE, Davidoff A, Rijcken TH, Stark DD. Hepatic iron concentration: noninvasive estimation by means of MR imaging techniques. Radiology 1999;212:227- 234.
63. Alustiza JM, Emparanza JI, Aldazabal P, et al. [Standardization of the quantification of iron concentration in the liver by magnetic resonance imaging]. Radiologia 2012;54:149-154.
64. Virtanen JM, Komu ME, Parkkola RK. Quantitative liver iron measurement by magnetic resonance imaging: in vitro and in vivo assessment of the liver to muscle signal intensity and the R2∗ methods. Magn Reson Imaging 2008;26:1175-1182.
65. Rose C, Vandevenne P, Bourgeois E, Cambier N, Ernst O. Liver iron content assessment by routine and simple magnetic resonance imaging procedure in highly transfused patients. Eur J Haematol 2006;77:145-149.
66. Papakonstantinou O, Foufa K, Benekos O, et al. Use of fat suppression in R(2) relaxometry with MRI for the quantification of tissue iron overload in beta-thalassemic patients. Magn Reson Imaging 2012;30:926-933.
67. Wood JC, Ghugre N. Magnetic resonance imaging assessment of excess iron in thalassemia, sickle cell disease and other iron overload diseases. Hemoglobin 2008;32:85-96.
68. Bulte JW, Miller GF, Vymazal J, Brooks RA, Frank JA. Hepatic hemosiderosis in non-human primates: quantification of liver iron using different field strengths. Magn Reson Med 1997;37: 530-536.
69. Clark PR, Chua-anusorn W, St Pierre TG. Bi-exponential proton transverse relaxation rate (R2) image analysis using RF field intensity-weighted spin density projection: potential for R2 measurement of iron-loaded liver. Magn Reson Imaging 2003;21: 519-530.
70. Wozniak JR, Lim KO. Advances in white matter imaging: a review of in vivo magnetic resonance methodologies and their applicability to the study of development and aging. Neurosci Biobehav Rev 2006;30:762-774.
71. Israel J, Unger E, Buetow K, Brown T, Blumberg B, London WT. Correlation between liver iron content and magnetic resonance imaging in rats. Magn Reson Imaging 1989;7:629-634.
72. Kaltwasser JP, Gottschalk R, Schalk KP, Hartl W. Non-invasive quantitation of liver iron-overload by magnetic resonance imaging. Br J Haematol 1990;74:360-363.
73. Dixon RM, Styles P, al-Refaie FN, et al. Assessment of hepatic iron overload in thalassemic patients by magnetic resonance spectroscopy. Hepatology 1994;19:904-910.
74. Wang ZJ, Haselgrove JC, Martin MB, et al. Evaluation of iron overload by single voxel MRS measurement of liver T2. J Magn Reson Imaging 2002;15:395-400.
75. Pavitt HL, Aydinok Y, El-Beshlawy A, et al. The effect of reducing repetition time TR on the measurement of liver R2 for the purpose of measuring liver iron concentration. Magn Reson Med 2011;65:1346-1351.
76. St-Pierre TG, El-Beshlawy A, Elalfy M, et al. Multicenter validation of spin-density projection-assisted R2-MRI for the noninvasive measurement of liver iron concentration. J Magn Reson Imaging [Epub ahead of print].
77. Hamilton G, Middleton MS, Bydder M, et al. Effect of PRESS and STEAM sequences on magnetic resonance spectroscopic liver fat quantification. J Magn Reson Imaging 2009;30:145- 152.
78. Hamilton G, Yokoo T, Bydder M, et al. In vivo characterization of the liver fat (1)H MR spectrum. NMR Biomed 2011;24:784-790.
79. Sharma P, Kitajima HD, Zhong X, Kalb B, Martin DR. Compartmental analysis of R2 measurements of hepatic lipid and iron in vivo using breath-hold multi-echo 1H spectroscopy (HISTO). In: Proc 19th Annual Meeting ISMRM, Montreal, Canada; 2011. p 738.
80. Hamilton G, Middleton M, Cunha G, Sirlin C. Effect of gadolinium-based contrast agent on the relaxation properties of water and fat in human liver as measured in vivo by 1H MRS. In: Proc 21st Annual Meeting ISMRM, Salt Lake City; 2013. p 815.
81. Jensen JH, Tang H, Tosti CL, et al. Separate MRI quantification of dispersed (ferritin-like) and aggregated (hemosiderin-like) storage iron. Magn Reson Med 2010;63:1201-1209.
82. Tang H, Jensen JH, Sammet CL, et al. MR characterization of hepatic storage iron in transfusional iron overload. J Magn Reson Imaging 2014;39:307-316.
83. Hernando D, Kramer HJ, Reeder SB. Multipeak fat-corrected complex R2∗ relaxometry: theory, optimization, and clinical validation. Magn Reson Med 2013;70:1319-1331.
84. Ghugre NR, Enriquez CM, Coates TD, Nelson MD Jr, Wood JC. Improved R2∗ measurements in myocardial iron overload. J Magn Reson Imaging 2006;23:9-16.
85. He T, Gatehouse PD, Smith GC, Mohiaddin RH, Pennell DJ, Firmin DN. Myocardial T2∗ measurements in iron-overloaded thalassemia: An in vivo study to investigate optimal methods of quantification. Magn Reson Med 2008;60:1082-1089.
86. Yin X, Shah S, Katsaggelos AK, Larson AC. Improved R2∗ measurement accuracy with absolute SNR truncation and optimal coil combination. NMR Biomed 2010;23:1127-1136.
87. Feng Y, He T, Feng M, et al. Improved pixel-by-pixel MRI R2∗ relaxometry by nonlocal means. Magn Reson Med [Epub ahead of print].
88. Vasanawala SS, Yu H, Shimakawa A, Jeng M, Brittain JH. Estimation of liver T∗2 in transfusion-related iron overload in patients with weighted least squares T∗2 IDEAL. Magn Reson Med 2012;67:183-190.
89. Yu H, Shimakawa A, McKenzie CA, et al. Phase and amplitude correction for multi-echo water-fat separation with bipolar acquisitions. J Magn Reson Imaging 2010;31:1264-1271.
90. Szczepaniak LS, Nurenberg P, Leonard D, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005;288: 462-468.
91. Hernando D, Kuhn JP, Mensel B, et al. R2∗ estimation using "inphase" echoes in the presence of fat: the effects of complex spectrum of fat. J Magn Reson Imaging 2013;37:717-726.
92. Wehrli FW, Ford JC, Haddad JG. Osteoporosis: clinical assessment with quantitative MR imaging in diagnosis. Radiology 1995;196:631-641.
93. Dahnke H, Schaeffter T. Limits of detection of SPIO at 3.0 T using T2∗ relaxometry. Magn Reson Med 2005;53:1202-1206.
94. Bydder GM, Steiner RE, Blumgart LH, Khenia S, Young IR. MR imaging of the liver using short TI inversion recovery sequences. J Comput Assist Tomogr 1985;9:1084-1089.
95. Haase A, Frahm J, Hanicke W, Matthaei D. 1H NMR chemical shift selective (CHESS) imaging. Phys Med Biol 1985;30:341-344.
96. Meyer CH, Pauly JM, Macovski A, Nishimura DG. Simultaneous spatial and spectral selective excitation. Magn Reson Med 1990; 15:287-304.
97. Kuhn JP, Hernando D, Munoz Del Rio A, et al. Effect of multipeak spectral modeling of fat for liver iron and fat quantification: correlation of biopsy with MR imaging results. Radiology 2012; 265:133-142.
98. Fernandez-Seara MA, Wehrli FW. Postprocessing technique to correct for background gradients in image-based R∗(2) measurements. Magn Reson Med 2000;44:358-366.
99. An H, Lin W. Cerebral oxygen extraction fraction and cerebral venous blood volume measurements using MRI: effects of magnetic field variation. Magn Reson Med 2002;47:958-966.
100. Yang X, Sammet S, Schmalbrock P, Knopp MV. Postprocessing correction for distortions in T2∗ decay caused by quadratic cross-slice B0 inhomogeneity. Magn Reson Med 2010;63:1258- 1268.
101. Baudrexel S, Volz S, Preibisch C, et al. Rapid single-scan T2∗- mapping using exponential excitation pulses and image-based correction for linear background gradients. Magn Reson Med 2009;62:263-268.
102. Hernando D, Vigen KK, Shimakawa A, Reeder SB. R2∗ mapping in the presence of macroscopic B(0) field variations. Magn Reson Med 2012;68:830-840.
103. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2∗) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001;22:2171-2179.
104. Hankins JS, McCarville MB, Loeffler RB, et al. R2∗ magnetic resonance imaging of the liver in patients with iron overload. Blood 2009;113:4853-4855.
105. Christoforidis A, Perifanis V, Spanos G, et al. MRI assessment of liver iron content in thalassamic patients with three different protocols: comparisons and correlations. Eur J Haematol 2009; 82:388-392.
106. Garbowski MW, Carpenter JP, Smith G, Pennell DJ, Porter JB. Calibration of improved T2∗ method for the estimation of liver iron concentration in transfusional iron overload. 51st Annual Meeting of the American-Society of Hematology, Vol. 114. New Orleans; 2009. p 791.
107. Westwood MA, Anderson LJ, Firmin DN, et al. Interscanner reproducibility of cardiovascular magnetic resonance T2∗ measurements of tissue iron in thalassemia. J Magn Reson Imaging 2003;18:616-620.
108. Westwood MA, Firmin DN, Gildo M, et al. Intercentre reproducibility of magnetic resonance T2∗ measurements of myocardial iron in thalassaemia. Int J Cardiovasc Imaging 2005;21:531-538.
109. Tanner MA, He T, Westwood MA, Firmin DN, Pennell DJ, Thalassemia International Federation Heart TI. Multi-center validation of the transferability of the magnetic resonance T2∗ technique for the quantification of tissue iron. Haematologica 2006;91:1388-1391.
110. Ramazzotti A, Pepe A, Positano V, et al. Multicenter validation of the magnetic resonance T2∗ technique for segmental and global quantification of myocardial iron. J Magn Reson Imaging 2009; 30:62-68.
111. Kirk P, He T, Anderson LJ, et al. International reproducibility of single breathhold T2∗ MR for cardiac and liver iron assessment among five thalassemia centers. J Magn Reson Imaging 2010; 32:315-319.
112. Meloni A, Rienhoff HY Jr, Jones A, Pepe A, Lombardi M, Wood JC. The use of appropriate calibration curves corrects for systematic differences in liver R2∗ values measured using different software packages. Br J Haematol 2013;161:888-891.
113. Qazi N, Hernando D, Reeder SB. Robustness of R2∗ mapping for liver iron assessment at 1.5T and 3T. In: Proc 21st Annual Meeting ISMRM, Salt Lake City; 2013.
114. Storey P, Thompson AA, Carqueville CL, Wood JC, de Freitas RA, Rigsby CK. R2∗ imaging of transfusional iron burden at 3T and comparison with 1.5T. J Magn Reson Imaging 2007;25: 540-547.
115. Anwar M, Wood J, Manwani D, Taragin B, Oyeku SO, Peng Q. Hepatic iron quantification on 3 Tesla (3 T) magnetic resonance (MR): technical challenges and solutions. Radiol Res Pract 2013; 2013:628150.
116. Meloni A, Positano V, Keilberg P, et al. Feasibility, reproducibility, and reliability for the T∗2 iron evaluation at 3 T in comparison with 1.5 T. Magn Reson Med 2012;68:543-551.
117. Taviani V, Johnson KM, Hernando D, Reeder SB. Single breathhold 3D radial imaging for R2∗ and fat fraction quantification in the liver. In: Proc 21st Annual Meeting ISMRM. Salt Lake City; 2013. p 2449.
118. Ou P, Zhao Y, Fawal SE, Banka P, Powell AJ. Cardiac T2 measurements in patients with iron overload: a comparison of imaging parameters and analysis techniques. Magn Reson Imaging 2012;30:641-648.
119. Yablonskiy DA, Haacke EM. Theory of NMR signal behavior in magnetically inhomogeneous tissues: the static dephasing regime. Magn Reson Med 1994;32:749-763.
120. Tanimoto A, Pouliquen D, Kreft BP, Stark DD. Effects of spatial distribution on proton relaxation enhancement by particulate iron oxide. J Magn Reson Imaging 1994;4:653-657.
121. Tanimoto A, Oshio K, Suematsu M, Pouliquen D, Stark DD. Relaxation effects of clustered particles. J Magn Reson Imaging 2001;14:72-77.
122. Weisskoff RM, Zuo CS, Boxerman JL, Rosen BR. Microscopic susceptibility variation and transverse relaxation: theory and experiment. Magn Reson Med 1994;31:601-610.
123. Angelucci E, Muretto P, Nicolucci A, et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood 2002;100:17-21.
124. Carneiro AA, Fernandes JP, de Araujo DB, et al. Liver iron concentration evaluated by two magnetic methods: magnetic resonance imaging and magnetic susceptometry. Magn Reson Med 2005;54:122-128.
125. Taouli B, Koh DM. Diffusion-weighted MR imaging of the liver. Radiology 2010;254:47-66.
126. Henninger B, Kremser C, Rauch S, et al. Evaluation of MR imaging with T1 and T2∗ mapping for the determination of hepatic iron overload. Eur Radiol 2012;22:2478-2486.
127. Wood JC, Otto-Duessel M, Aguilar M, et al. Cardiac iron determines cardiac T2∗, T2, and T1 in the gerbil model of iron cardiomyopathy. Circulation 2005;112:535-543.
128. Feng Y, He T, Carpenter JP, et al. In vivo comparison of myocardial T1 with T2 and T2∗ in thalassaemia major. J Magn Reson Imaging 2013;38:588-593.
129. de Rochefort L, Liu T, Kressler B, et al. Quantitative susceptibility map reconstruction from MR phase data using bayesian regularization: validation and application to brain imaging. Magn Reson Med 2010;63:194-206.
130. de Rochefort L, Brown R, Prince MR, Wang Y. Quantitative MR susceptibility mapping using piece-wise constant regularized inversion of the magnetic field. Magn Reson Med 2008;60:1003-1009.
131. Liu J, Liu T, de Rochefort L, et al. Morphology enabled dipole inversion for quantitative susceptibility mapping using structural consistency between the magnitude image and the susceptibility map. Neuroimage 2012;59:2560-2568.
132. Langkammer C, Schweser F, Krebs N, et al. Quantitative susceptibility mapping (QSM) as a means to measure brain iron? A post mortem validation study. Neuroimage 2012;62:1593-1599.
133. Holt RW, Diaz PJ, Duerk JL, Bellon EM. MR susceptometry: an external-phantom method for measuring bulk susceptibility from field-echo phase reconstruction maps. J Magn Reson Imaging 1994;4:809-818.
134. Holt RW. MRI susceptometry: theory and robustness of an external phantom method for measuring bulk susceptibility from MRI field echo phase reconstruction maps applied to human liver iron overload. Cleveland, OH: Case Western Reserve University; 1993.
135. Chu Z, Cohen AR, Muthupillai R, Chung T, Wang ZJ. MRImeasurement of hepatic magnetic susceptibility-phantom validation and normal subject studies. Magn Reson Med 2004;52:1318- 1327.
136. Wang ZJ, Li S, Haselgrove JC. Magnetic resonance imaging measurement of volume magnetic susceptibility using a boundary condition. J Magn Reson 1999;140:477-481.
137. Wang ZJ, Fischer R, Chu Z, et al. Assessment of cardiac iron by MRI susceptometry and R2∗ in patients with thalassemia. Magn Reson Imaging 2010;28:363-371.
138. Taylor BA, Loeffler RB, Song R, McCarville MB, Hankins JS, Hillenbrand CM. Simultaneous field and R2∗ mapping to quantify liver iron content using autoregressive moving average modeling. J Magn Reson Imaging 2012;35:1125-1132 [published erratum appears in J Magn Reson Imaging, early view, doi 1110.1002/jmri.24135].
139. Hernando D, Cook RJ, Diamond C, Reeder SB. Magnetic susceptibility as a B0 field strength independent MRI biomarker of liver iron overload. Magn Reson Med 2013;70:648-656.
140. Hackett S, Chua-anusorn W, Pootrakul P, St Pierre TG. The magnetic susceptibilities of iron deposits in thalassaemic spleen tissue. Biochim Biophys Acta 2007;1772:330-337.